ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GRPR-targeting Radioconjugate LY4257496

Its studies are mostly in Breast Neoplasms, led by Eli Lilly.

Furthest: phase 1, since Jul 30, 20251 company-led study, 1 open or runningNext primary completion: Apr 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly11 open or runningphase 1since Jul 30, 2025Jul 30, 2025Apr 2030phase 1 · NCT07114601

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 30, 2025First study: phase 1 study in Breast NeoplasmsFirst studyNCT07114601 · 421 planned · United States, Canada, China and more

Ahead

  1. Apr 2030Primary completion: phase 1 study in Breast NeoplasmsNCT07114601

TargetBeta

GRPR →read by rule
“A radioconjugate consisting of a gastrin-releasing peptide receptor (GRPR)-targeting ligand, ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07114601Breast Neoplasms · United States, Canada, China and more1RecruitingApr 2030421

How it is read

Names in the registry

  • “LY4257496”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.